1-氮杂双环[2.2.1]庚烷-3-甲酰氯 | 130513-77-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-氮杂双环[2.2.1]庚烷-3-甲酰氯
• 英文名称: (3S,4R)-1-azabicyclo[2.2.1]heptane-3-carbonyl chloride
• CAS: 130513-77-8
• 化学式: C₇H₁₀ClNO
• 分子量: 159.615
• InChiKey: CJUYFGBJBPNHFJ-NTSWFWBYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-氮杂双环[2.2.1]庚烷-3-甲酰氯 在 吡啶 作用下， 以 四氢呋喃 、 乙醚 、 乙腈 为溶剂， 反应 3.5h， 生成 endo-3-acetyl-1-azabicyclo<2.2.1>heptane
  参考文献：
  名称：

  Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands

  摘要：

  The effect of variation of the 1-azabicyclic substituent on the novel 1,2,3-triazol-4-yl-, 1,2,4-triazol-1-yl-, tetrazol-5-yl-, and tetrazol-2-yl-based muscarinic receptor ligands ha, been studied, and the exo-azabicyclic[2.2.1]hept-3-yl substituent was found to give the most potent and efficacious compounds. In addition, variation of the second substituent on 1,2,4-triazol-1-yl- and tetrazol-2-yl-based muscarinic receptor ligands has yielded a series of novel compounds with high potencies and efficacies, ranging from full agonists to antagonists. Small lipophilic electron withdrawing substituents give potent but low efficacy compounds, while small polar electron donating substituents give potent and efficacious compounds. The activity of these compounds is described in terms of a model of the receptor involving lipophilic and hydrogen bonding interactions. These compounds provide muscarinic ligands with high potency and a range of efficacies suitable for testing as candidate drugs in the treatment of Alzheimer's disease.

  DOI：

  10.1021/jm00091a007
• 作为产物：
  描述：

  ethyl (3R,4S)-1-azabicyclo<2.2.1>heptane-3-carboxylate 在 盐酸 、 氯化亚砜 作用下， 反应 4.25h， 生成 1-氮杂双环[2.2.1]庚烷-3-甲酰氯
  参考文献：
  名称：

  Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands

  摘要：

  The effect of variation of the 1-azabicyclic substituent on the novel 1,2,3-triazol-4-yl-, 1,2,4-triazol-1-yl-, tetrazol-5-yl-, and tetrazol-2-yl-based muscarinic receptor ligands ha, been studied, and the exo-azabicyclic[2.2.1]hept-3-yl substituent was found to give the most potent and efficacious compounds. In addition, variation of the second substituent on 1,2,4-triazol-1-yl- and tetrazol-2-yl-based muscarinic receptor ligands has yielded a series of novel compounds with high potencies and efficacies, ranging from full agonists to antagonists. Small lipophilic electron withdrawing substituents give potent but low efficacy compounds, while small polar electron donating substituents give potent and efficacious compounds. The activity of these compounds is described in terms of a model of the receptor involving lipophilic and hydrogen bonding interactions. These compounds provide muscarinic ligands with high potency and a range of efficacies suitable for testing as candidate drugs in the treatment of Alzheimer's disease.

  DOI：

  10.1021/jm00091a007

文献信息

• CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS
  申请人：SmithKline Beecham plc

  公开号：EP0874809B1

  公开（公告）日：2003-08-27
• AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0934316A1

  公开（公告）日：1999-08-11
• US6020368A
  申请人：——

  公开号：US6020368A

  公开（公告）日：2000-02-01
• US6121281A
  申请人：——

  公开号：US6121281A

  公开（公告）日：2000-09-19
• US6239175B1
  申请人：——

  公开号：US6239175B1

  公开（公告）日：2001-05-29